<p>Leerink Partners 分析師 Faisal Khurshid 今天維持了對 Rhythm Pharmaceuticals 的買入評級，並設定了目標價為 142.00 美元。</p>
<h3>在 TipRanks Premium 上享受 50% 折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>Khurshid 關注醫療保健行業，重點關注 aTyr Pharma、Rhythm Pharmaceuticals 和 Nurix Therapeutics 等股票。根據 TipRanks 的數據，Khurshid 推薦股票的平均回報率為 55.8%，成功率為 59.02%。</p>
<p>除了 Leerink Partners，Rhythm Pharmaceuticals 還在 12 月 12 日的報告中獲得了摩根士丹利的 Michael Ulz 的買入評級。然而，在同一天，TR | OpenAI – 4o 對 Rhythm Pharmaceuticals (NASDAQ: RYTM) 重申了持有評級。</p>

RYTM

<p>Leerink Partners 的分析師 Faisal Khurshid 對 Rhythm Pharmaceuticals 維持了買入評級，目標價為 142.00 美元。Khurshid 覆蓋醫療保健行業，推薦股票的平均回報率為 55.8%，成功率為 59.02%。Rhythm Pharmaceuticals 還獲得了摩根士丹利的買入評級，而 TR 則重申了持有評級</p>

<p>Leerink Partners analyst Faisal Khurshid maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $142.00.</p>
<div class="lb-trans"><p>Leerink Partners 分析師 Faisal Khurshid 今天維持了對 Rhythm Pharmaceuticals 的買入評級，並設定了目標價為 142.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Rhythm Pharmaceuticals, and Nurix Therapeutics. According to TipRanks, Khurshid has an average return of 55.8% and a 59.02% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Khurshid 關注醫療保健行業，重點關注 aTyr Pharma、Rhythm Pharmaceuticals 和 Nurix Therapeutics 等股票。根據 TipRanks 的數據，Khurshid 推薦股票的平均回報率為 55.8%，成功率為 59.02%。</p>
</div><p>In addition to Leerink Partners, Rhythm Pharmaceuticals also received a Buy from Morgan Stanley’s Michael Ulz in a report issued on December 12. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).</p>
<div class="lb-trans"><p>除了 Leerink Partners，Rhythm Pharmaceuticals 還在 12 月 12 日的報告中獲得了摩根士丹利的 Michael Ulz 的買入評級。然而，在同一天，TR | OpenAI – 4o 對 Rhythm Pharmaceuticals (NASDAQ: RYTM) 重申了持有評級。</p>
</div>

Leerink Partners 堅持對 Rhythm Pharmaceuticals (RYTM) 的買入評級